Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan and Biocon have first pegfilgrastim in US

Executive Summary

Mylan has received approval from the US Food and Drug Administration (FDA) for the first biosimilar of Amgen’s Neulasta (pegfilgrastim) in the US, with the Fulphila (pegfilgrastim-jmdb) 6mg/0.6ml injectable biosimilar co-developed with Biocon. Expected to be “the first biosimilar pegfilgrastim available in the US”, Fulphila is set to be launched “in the coming weeks”, Mylan anticipates, with a “suite of patient services” to further support patients and caregivers with treatment.

You may also be interested in...



Amgen Pulled Up Over Anti-Biosimilar Pegfilgrastim Promotion

Amgen has been rebuked by the FDA over promotion for its unique Neulasta Onpro on-body injector version of pegfilgrastim, in which the firm made false or misleading claims about its benefit compared to a pre-filled syringe formulation of pegfilgrastim, where biosimilar competition exists.

FDA Is Urged To Make All Biosimilar Insulins Interchangeable

As part of feedback on the future of insulin biosimilars in the wake of FDA guidance over transitioning insulins to biologic status, the agency has been urged to deem all biosimilar insulins interchangeable as well as to push back against originator attempts to shield individual product ‘ecosystems’ from competition.

Joint Mission: FDA And VA Partner On Device Development Initiative

The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.

Latest News
See All
UsernamePublicRestriction

Register

GB000778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel